Evidence map›Paper›PMID 38782452›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2024

Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer.

Eric Rios-Doria, Nadeem R Abu-Rustum, Kaled M Alektiar, Vicky Makker, Ying L Liu, Dmitriy Zamarin, Claire F Friedman, Carol Aghajanian, Lora H Ellenson, Sarah Chiang and 3 more

Abstract read
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eric Rios-DoriaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-5494-8775
Nadeem R Abu-RustumDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-9689-1298
Kaled M AlektiarDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Vicky MakkerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ying L LiuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Dmitriy ZamarinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Claire F FriedmanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Carol AghajanianDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lora H EllensonDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sarah ChiangDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-9698-0936
Britta WeigeltDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jennifer J MuellerDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-0365-7510
Mario M LeitaoDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA leitaom@mskcc.org.ORCID 0000-0003-0818-3836

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749
6 · The paper itself

Abstract

objectiveWe assessed the prognosis and molecular subtypes of early stage endometrioid endometrial cancer with isolated tumor cells within sentinel lymph nodes (SLNs) compared with node negative disease.

methodsPatients diagnosed with stage IA, IB, or II endometrioid endometrial cancer and primary surgical management were identified from January 1, 2007 to December 31, 2019. All SLNs underwent ultrastaging according to the institutional protocol. Patients with cytokeratin positive cells, micrometastases, and macrometastases were excluded. Clinical, pathology, and molecular subtype data were reviewed.

resultsOverall, 1214 patients with early stage endometrioid endometrial cancer met the inclusion criteria, of whom 1089 (90%) had node negative disease and 125 (10%) had isolated tumor cells. Compared with node negative disease, the presence of isolated tumor cells had a greater association with deep myometrial invasion, lymphovascular space invasion, receipt of adjuvant therapy, and adjuvant chemotherapy with or without radiation (p<0.01). There was no significant difference in survival rates between patients with isolated tumor cells and node negative disease (3 year progression free survival rate 94% vs 91%, respectively, p=0.21; 3 year overall survival rate 98% vs 96%, respectively, p=0.45). Progression free survival did not significantly differ among patients with isolated tumor cells who received no adjuvant therapy or chemotherapy with or without radiation (p=0.31). There was no difference in the distribution of molecular subtypes between patients with isolated tumor cells (n=28) and node negative disease (n=194; p=0.26). Three year overall survival rates differed significantly when stratifying the entire cohort by molecular subtype (p=0.04).

conclusionsPatients with isolated tumor cells demonstrated less favorable uterine pathologic features and received more adjuvant treatment with similar survival compared with patients with nodenegative disease. Among the available data, molecular classification did not have a significant association with the presence of isolated tumor cells, although copy number-high status was a poor prognostic indicator in early stage endometrioid endometrial cancer.

Indexed as

Carcinoma, EndometrioidEndometrial NeoplasmsNeoplasm StagingAdultAgedAged, 80 and overFemaleHumansMiddle AgedPrognosisRetrospective StudiesSentinel Lymph NodeEndometrial NeoplasmsUterine Cancer

Identifiers

PMID38782452
PMCPMC12044596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.